In summary, these results confirm that combinations of BH3 mimetics and inhibitors of BCR signaling are effective in CLL, supporting recent clinical studies [30, 31] and current trial activity (NCT02756897, NCT03580928, NCT03868722). This evidence concerns the gene BCR and B-cell chronic lymphocytic leukemia.